Toni Choueiri, MD, on Updated Follow-up Data in RCC at 2021 ASCO

Video

Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about trials of combination therapies that had updated data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Transcription:

There were some studies that were not presented for the first time, but more analysis. So, KEYNOTE-426 [NCT02853331], for example, that [led to the approval of the combination] of pembrolizumab [Keytruda] and axitinib [Inlyta] now has a long median follow-up.

I think one of the issues with these VEGF/IO [immunotherapy] combinations [is that] they never have the same follow up as the IO/IO combinations like nivolumab [Opdivo]/ipilimumab [Yervoy]. Now, pembrolizumab/axitinib has more follow up [and it will] be interesting to look at the data in detail. There are data also for a newer combination of pembrolizumab/lenvatinib [Lenvima] that was presented a couple of months ago. There are data now about quality of life, we know this patient[-reported outcome].

There’s a lot of good stuff to be presented and I hope folks will follow all the data virtually that is coming in renal cell cancer, but also in [genitourinary] cancer in general.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content